Medications for Graft Rejection

19 results

  • Everolimus (everolimus)

    (Everolimus)
    Ascend Laboratories, LLC
    Usage: Everolimus tablets are indicated for the prevention of organ rejection in adult kidney transplant patients at low to moderate immunologic risk and in liver transplant patients, administered with specific immunosuppressants. Therapeutic drug monitoring is recommended. Safety has not been established for high-risk kidney recipients or in pediatric patients.

  • Mycophenolate mofetil (mycophenolate mofetil)

    (Mycophenolate mofetil)
    Strides Pharma Science Limited
    Usage: Mycophenolate mofetil (MMF) is indicated for the prevention of organ rejection in adult and pediatric recipients (3 months and older) of kidney, heart, or liver transplants, used alongside other immunosuppressants.

  • Mycophenolate mofetil (mycophenolate mofetil)

    (Mycophenolate mofetil)
    AVEO Pharmaceuticals Inc
    Usage: Mycophenolate mofetil (MMF) is indicated for preventing organ rejection in patients undergoing allogeneic kidney, heart, or liver transplants, used in conjunction with other immunosuppressants.

  • Mycophenolate mofetil (mycophenolate mofetil)

    (Mycophenolate mofetil)
    Strides Pharma Inc.
    Usage: Mycophenolate mofetil (MMF) is indicated for the prevention of organ rejection in adult and pediatric patients (3 months and older) undergoing allogeneic kidney, heart, or liver transplants, used alongside other immunosuppressants.

  • Mycophenolic acid (mycophenolic acid)

    (Mycophenolic Acid)
    Accord Healthcare Inc.
    Usage: Mycophenolic acid delayed release tablets are indicated for preventing organ rejection in adult and pediatric kidney transplant patients, used alongside cyclosporine and corticosteroids. They should not be interchanged with mycophenolate mofetil without medical supervision due to differing absorption rates.

  • Mycophenolic acid (mycophenolic acid)

    (mycophenolic acid)
    PD-Rx Pharmaceuticals Inc
    Usage: Mycophenolic acid delayed-release tablets are indicated for the prophylaxis of organ rejection in adult and pediatric patients (5 years and older) after kidney transplant, used in combination with cyclosporine and corticosteroids. They should not be substituted for mycophenolate mofetil without physician oversight.

  • Mycophenolic acid (mycophenolic acid)

    (mycophenolic acid)
    CONCORD BIOTECH LIMITED
    Usage: Mycophenolic acid delayed-release tablets are indicated for preventing organ rejection in kidney transplant patients aged 5 and older, used alongside cyclosporine and corticosteroids. It is not interchangeable with mycophenolate mofetil without physician supervision due to differing absorption rates.

  • Mycophenolic acid (mycophenolic acid)

    (MYCOPHENOLIC ACID)
    A-S Medication Solutions
    Usage: Mycophenolic acid delayed-release tablets are indicated for preventing organ rejection in adult and pediatric kidney transplant patients, used in combination with cyclosporine and corticosteroids. Interchangeability with mycophenolate mofetil (MMF) products requires physician supervision due to differing absorption rates.

  • Mycophenolic acid (mycophenolic acid)

    (Mycophenolic Acid)
    Biocon Pharma Inc.
    Usage: Mycophenolic acid delayed-release tablets are indicated for the prophylaxis of organ rejection in adult and pediatric kidney transplant patients (5 years and older). They should be used alongside cyclosporine and corticosteroids, and not interchangeably with mycophenolate mofetil products without physician supervision.

  • Mycophenolic acid (mycophenolic acid)

    (Mycophenolic Acid)
    AMTA LABS LIMITED
    Usage: Mycophenolic Acid Delayed-Release Tablets are indicated for the prophylaxis of organ rejection in adult and pediatric patients (5 years and older) post-kidney transplant, used in combination with cyclosporine and corticosteroids. Interchange with mycophenolate mofetil products requires physician supervision due to differing absorption rates.